Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | BCL2 | P10415 | 2/20 | 0.46 |
| ▸ | BID | P55957 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.45 |
| ▸ | BCL2L10 | Q9HD36 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sumacetamol SCHEMBL5185790 | 1.00 | GAA (0.55) | GAAMAPTHSD17B10HPGDALDH1A1 | |
| SCHEMBL13637924 | 0.90 | KMT2A (0.51) | GAAMAPTHSD17B10HPGDALDH1A1 | |
| SCHEMBL1133950 | 0.88 | KMT2A (0.55) | GAAMAPTHSD17B10HPGDALDH1A1 | |
| SCHEMBL1133954 | 0.87 | EPHX2 (0.52) | GAAMAPTHSD17B10HPGDALDH1A1 | |
| SCHEMBL1133956 | 0.87 | EPHX2 (0.52) | GAAMAPTHSD17B10HPGDALDH1A1 | |
| SCHEMBL18211946 | 0.87 | GAA (0.54) | GAAMAPTHSD17B10HPGDALDH1A1 | |
| SCHEMBL11085230 | 0.86 | GAA (0.53) | GAAMAPTHSD17B10HPGDALDH1A1 | |
| SCHEMBL11085232 | 0.86 | GAA (0.53) | GAAMAPTHSD17B10HPGDALDH1A1 | |
| SCHEMBL1133962 | 0.85 | KMT2A (0.55) | MAPTHSD17B10HPGDALDH1A1KDM4E | |
| SCHEMBL13637985 | 0.84 | KMT2A (0.54) | GAAMAPTHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1468111-A | Pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraine | �Ʒ� | 2004-01-14 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-9951001-B2 | Hepatoprotectant acetaminophen mutual prodrugs | ACORDA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. | 2016-11-10 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-4482495-A | CHEMICAL INTERMEDIATES FOR ANALGESICS | STERLING DRUG INC. (US) | 1984-11-13 | — | — | US | disclosed |
| EP-0100168-A2 | Processes for preparing tablets by a modified 'wet-granulation' technique | Rogerson, Alan George (GB) | 1984-02-08 | — | — | EP | disclosed |
| US-4405800-A | ANALGESICS | STERLING DRUG INC. (US) | 1983-09-20 | — | — | US | disclosed |
| US-4361703-A | ANALGESICS | STERLING DRUG INC. (US) | 1982-11-30 | — | — | US | disclosed |
| US-4181719-A | Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates | STERLING DRUG INC. (US) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | PTGS1, HPGD, PYGL | GAA 2544/4885MAPT 2608/4885HSD17B10 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.